Business Monitor International


Mozambique Pharmaceuticals & Healthcare Report

Published 18 August 2014

  • 61 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Mozambique Pharmaceuticals & Healthcare Report

BMI View: Mozambique is rich in natural resources making it a fast growing economy, both government and foreign investors are taking steps to improve the quality imported medicines and healthcare facilities. Vaccination programs and trials are being put into place, particularly for malaria and HIV immunisation, to help combat the county ' s high burden of disease. However, Mozambique ' s pharmaceutical market suffers from an abundance of counterfeit medicines in circulation partly. It ' s high dependence on costly imported drugs combined with a poor regulatory framework and weak intellectual property protection continue to impede market growth potential.

Headline Expenditure Forecasts

  • Pharmaceuticals: MZN5.80bn (USD192mn) in 2013 to MZN6.24bn (USD201mn) in 2014; +7.7% in local currency and +4.8% in US dollar terms.  Forecast revised up from last quarter to better suit current market conditions.

  • Healthcare: MZN30.30bn (USD1.00bn) in 2013 to MZN31.49bn (USD1.02bn) in 2014; +3.9% in local currency and +1.1% in US dollar terms.  Forecast revised up from last quarter to better suit current market conditions.

Risk/Reward Rating

Mozambique has a score of 25.9 out of 100 in our Pharmaceutical Risk/Reward Rating (RRR) for Q414, ranking it 31st and the least attractive pharmaceutical market in the Middle East and Africa (MEA) region. While the country is posting good economic growth, political unrest is emerging as well as outbreaks of violence.

Key Trends And Developments

In July, allAfrica reports that pharmaceutical company GlaxoSmithKline (GSK) applied to the European Medicines Agency (EMA) for regulatory approval for its RTS,S malaria candidate vaccine, which is the first vaccine to offer protection against the disease. The vaccine must pass EU standards regardless of it being designed for use outside Europe and has been trialled in research centres in Africa including the Manhica Health Research Centre in the southern Mozambique. The vaccine could be...

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
12
Business Environment
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Mozambique 2010-2018)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2010-2018)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2010-2018)
20
Key Risks To BMI's Forecast Scenario
21
Macroeconomic Forecasts
22
Economic Analysis
22
Table: Mozambique's GDP By Expenditure, 2011-2018
27
Industry Risk Reward Ratings
28
Middle East & Africa Risk/Reward Ratings
28
Mozambique Risk/Reward Ratings
36
Rewards
36
Risks
36
Market Overview
38
Industry Trends And Developments
40
Epidemiology
40
Clinical Trials
42
Regulatory Development
44
Regulatory Development
44
Intellectual Property Issues
45
Pricing Regime
45
Competitive Landscape
46
Domestic Industry
46
Company Developments
46
Company Profile
48
Sociedade Mo-ambicana de Medicamentos (SMM)
48
Demographic Forecast
50
Table: Mozambique's Population By Age Group, 1990-2020 ('000)
51
Table: Mozambique's Population By Age Group, 1990-2020 (% of total)
52
Table: Mozambique's Key Population Ratios, 1990-2020
53
Table: Mozambique's Rural And Urban Population, 1990-2020
53
Glossary
54
Methodology
56
Pharmaceutical Expenditure Forecast Model
56
Healthcare Expenditure Forecast Model
56
Notes On Methodology
57
Risk/Reward Ratings Methodology
58
Ratings Overview
59
Table: Pharmaceutical Risk/Reward Ratings Indicators
59
Indicator Weightings
60

The Mozambique Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Mozambique Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Mozambican pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Mozambique to test other views - a key input for successful budgeting and strategic business planning in the Mozambican pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Mozambican pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Mozambique.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc